+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 12Years +
All Genders
ID06796699

Evaluation of GH56 Capsules for Safety and Early Effects in Patients with MTAP-Deleted Advanced Solid Tumors A Multi-Center, Single-Arm Phase IaIb Clinical Trial

Led by Suzhou Genhouse Bio Co., Ltd. · Updated on 2026-10-02

200

Participants Needed

25

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multicenter, single-arm, open-label phase IaIb clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of GH56 capsules in subjects with advanced solid tumors that have a deletion of the MTAP gene. The study includes patients who have failed or cannot tolerate standard treatments or have no effective standard therapy, and involves both adult and adolescent cohorts aged 12 years and older. Participants will receive GH56 capsules orally at varying doses during two parts of the study phase Ia dose escalation and phase Ib dose expansion. The dose expansion includes separate adult and adolescent groups and aims to identify the maximum tolerated dose and recommended dose for expansion. Treatment will continue according to the study schedule with close monitoring. During the trial, participants will undergo assessments including tumor measurements using RECIST v1.1 criteria, evaluation of adverse events for safety, laboratory tests for organ function, and pharmacokinetic and pharmacodynamic analyses. Researchers will monitor response rates, disease control, duration of response, and progression-free survival over approximately three years. Pregnancy tests and contraceptive requirements will be followed, and survival expectations must be at least 12 weeks.

CONDITIONS

Brief Title

A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors(G-MAP 101)

Research Team

B

Bo Ning, Master

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here